Johnson & Johnson JNJ

$272.98 -5.72 (-2.05%)

Valuation

Market cap
680,185,472,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.83
P/E (forward)
25.70
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
2,857,482
Avg volume
7,332,246
Day's range
$273.70 – $278.72
Shares out
2,407,310,000
Stochastic %K
53%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

LuisBarajas16 Nov 18, 6:02 PM
$BMY $INO $JNJ $MRK $PFE Legit post. Thanks for letting us know.
0 replies
SellasgpsCurativeBAT11 Nov 18, 5:44 PM
$INO $MRK $PFE $BMY $JNJ Big pharmaceuticals very aggressive BO due to $380 Billion in patent expirations in coming years. $INO Will be BO very soon! ✌️🙏❤️‍🩹
0 replies
SparkyReturns Nov 18, 5:34 PM
$ICU This will be a change in paradigm for so many indications and companies with related drugs and support for these condition. $JNJ $ABBV $MRK $LLY
0 replies
KryptonResearch14 Nov 18, 5:15 PM
My favorite Abstraction piece to work on yet! Biotech is set for a massive revolution as AI accelerates how we cure disease and it’s arguably the greatest AI application of them all. $XBI $LABU $JNJ $PFE $ABBV This month we look at this new paradigm and its investment ramifications. As always, abstractions are free to read: https://kryptonresearch.substack.com/p/volume-iii-in-search-of-a-cure
0 replies
seeitmarket Nov 18, 3:48 PM
$JNJ Even consumer staples getting hit hard. Johnson & Johnson with support at 50-day moving average. #IBDPartner @MarketSurge
1 replies
Benks Nov 18, 3:17 PM
Michael Frascello (Senior director $JNJ ) is in love with $SLS
0 replies
graywolf Nov 18, 3:16 PM
$SLS who is stepping up? $JNJ $MRK $PFE ?
1 replies
Estimize Nov 18, 2:30 PM
Wall St is expecting 2.91 EPS for $JNJ Q4 [Reporting 01/26 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 replies